Shanghai Institute of Materia Medica, Chinese Academy of Sciences;Suzhou Suplead Life Sciences Co., Ltd.
发明人:
申请号：
EP18860160.3
公开号：
EP3689875A1
申请日:
2018.08.29
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions.
